ArrowMark Colorado Holdings’s Tempest Therapeutics TPST Stock Holding History

ArrowMark Colorado Holdings’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-578	Closed	-$12.1M	–	438
2016 Q3	$12.1M	Sell	578 -16	-3%	-$289K	0.22%	112
2016 Q2	$9.04M	Buy	594 +43	+8%	+$982K	0.18%	118
2016 Q1	$15.3M	Sell	551 -83	-13%	-$1.75M	0.34%	90
2015 Q4	$18.1M	Sell	634 -54	-8%	-$1.78M	0.5%	70
2015 Q3	$17.1M	Buy	688 +648	+1,620%	+$43.6M	0.47%	66
2015 Q2	$3.36M	Buy	40 +12	+43%	+$1.1M	0.08%	180
2015 Q1	$2.81M	Buy	+28	New	+$3.73M	0.07%	174

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ArrowMark Colorado Holdings's TPST Position: Q4 2016 in Review

ArrowMark Colorado Holdings sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 578 shares — an estimated $12.1M sold.

ArrowMark Colorado Holdings first reported a position in TPST in Q1 2015 and held it in 7 quarters. The position peaked at $18.1M in Q4 2015. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

ArrowMark Colorado Holdings reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
ArrowMark Colorado Holdings sold 578 Tempest Therapeutics shares in Q4 2016, an estimated $12.1M.
ArrowMark Colorado Holdings first reported a position in Tempest Therapeutics in Q1 2015 and held it in 7 quarters.
ArrowMark Colorado Holdings's Tempest Therapeutics position peaked at $18.1M in Q4 2015.
84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.